Oculoplasty: Eyelid, Orbital, and Lacrimal Surgery for Function and Aesthetics — Cost, Top Hospitals & Success Rates | MyMedicPlus

Oculoplasty (ophthalmic plastic surgery, or oculoplastic surgery) is a subspecialty of ophthalmology encompassing surgical and non-surgical procedures on the eyelids, orbit (bony eye socket), lacrimal (tear drainage) system, and periorbital region. Oculoplastic surgeons hold dual training in ophthalmology (eye surgery) and plastic surgery principles, giving them uniquely specialised expertise in both the functional requirements of the eye and the aesthetic demands of the periorbital region — the most expressive and scrutinised area of the face.

The scope of oculoplasty is broad and diverse. Eyelid procedures constitute the largest component and include blepharoplasty (removal of excess eyelid skin and fat), ptosis repair (correction of drooping upper eyelid), entropion and ectropion repair (inward and outward eyelid turning), eyelid reconstruction following tumour excision or trauma, and eyelid retraction correction often related to thyroid eye disease. Orbital surgery addresses orbital fractures, orbital tumours, orbital decompression for thyroid eye disease, and enucleation or evisceration of a non-seeing eye with prosthetic fitting. Lacrimal system procedures correct watering eyes caused by nasolacrimal duct obstruction through dacryocystorhinostomy (DCR) — creating a new drainage pathway from the tear sac to the nasal cavity.

Non-surgical oculoplastic procedures include the use of botulinum toxin type A for brow ptosis, brow furrows (glabellar lines), periorbital wrinkles (crow's feet), hemifacial spasm, blepharospasm, and facial asymmetry; and injectable fillers for periorbital hollowing, tear trough deformity, and brow augmentation. The periorbital region presents unique challenges for filler injection due to the proximity of the globe and major orbital vessels, requiring precise technique and appropriate product selection.

Eyelid ptosis (drooping upper eyelid) is a common oculoplastic condition that can be congenital (present from birth) or acquired — caused by ageing aponeurotic dehiscence (separation of the levator aponeurosis), mechanical causes (heavy eyelid skin or tumours), myogenic causes (myasthenia gravis), or neurogenic causes (Horner syndrome, third cranial nerve palsy). Ptosis may impair the visual field significantly if the eyelid covers the visual axis, causing amblyopia in children. Blepharoplasty addresses dermatochalasis (excess upper eyelid skin) and herniated orbital fat causing puffiness, which may be purely cosmetic or may impair vision and cause brow ache in severe cases.

Thyroid eye disease (Graves ophthalmopathy) is one of the most complex conditions managed by oculoplastic surgeons, causing proptosis (bulging eyes), orbital congestion, corneal exposure, restricted ocular motility, and compressive optic neuropathy — all potentially requiring orbital decompression surgery. Orbital tumours (primary and metastatic), orbital wall fractures (blow-out fractures causing enophthalmos, diplopia), chalazion and eyelid cysts, lacrimal gland tumours, basal cell carcinomas and squamous cell carcinomas of the eyelid skin requiring wide excision and complex reconstruction, and involutional ectropion and entropion causing tearing, discomfort, and corneal injury are all within the scope of oculoplasty.

Candidates for oculoplastic procedures are individuals with functional visual or ocular symptoms (ptosis impeding vision, watering eyes from duct obstruction, corneal exposure from ectropion, or optic nerve compression from proptosis) or with significant cosmetic concerns about the periorbital area that impact quality of life. Functional indications generally take precedence and may receive insurance coverage. Cosmetic blepharoplasty candidates should be in good general health, non-smoking (or willing to stop peri-operatively), and have realistic expectations regarding the degree of rejuvenation achievable — blepharoplasty improves eyelid appearance but does not eliminate all orbital ageing changes.

Contraindications vary by procedure. For cosmetic blepharoplasty: significant dry eye syndrome (surgery can worsen corneal desiccation by reducing the blink barrier), glaucoma, or unstable systemic conditions that elevate surgical risk. For orbital surgery: active thyroid eye disease in the inflammatory phase (orbital decompression is deferred until the condition is stable for at least 6 months). For all procedures: anticoagulant therapy requires management planning with the prescribing physician, as even minor bleeding in the orbit can cause vision-threatening orbital haematoma.

Eyelid procedures include upper blepharoplasty (removal of skin and fat from the upper eyelid via an incision in the natural upper eyelid crease), lower blepharoplasty (transcutaneous or transconjunctival approach to address lower eyelid bags and excess skin), and Asian blepharoplasty (creation of an upper eyelid crease in patients without a supratarsal fold). Levator aponeurosis advancement or Mueller's muscle tucking (Fasanella-Servat procedure) correct ptosis depending on levator function. Frontalis sling surgery uses a silicone rod or fascia lata strip to connect the eyelid to the frontalis brow muscle for ptosis cases with poor levator function.

Orbital decompression for thyroid eye disease can be performed through transconjunctival, transnasal endoscopic, or combined approaches removing one, two, or three orbital walls to increase orbital volume and reduce proptosis. Endonasal DCR for nasolacrimal duct obstruction uses a nasal endoscope to create a fistula between the tear sac and nasal mucosa under direct vision, avoiding external facial incision. External DCR remains the gold standard with a 90-95% success rate. Botulinum toxin injection for blepharospasm, hemifacial spasm, and cosmetic periorbital applications is administered in the clinic setting without anaesthesia, with effects lasting 3-4 months. The precise surgical approach is determined after comprehensive ophthalmic examination, imaging of the orbit and periorbital structures where indicated, and functional assessment of eyelid mechanics, lacrimal drainage, and visual field, ensuring that both functional rehabilitation and aesthetic restoration are addressed within a unified surgical plan.

Ptosis repair restores the normal visual field and eliminates the compensatory chin-up head posture and brow-raising associated with compensated ptosis, with success rates exceeding 90% in experienced hands. Blepharoplasty consistently produces high satisfaction rates — multiple outcome studies document 85-95% patient satisfaction — and achieves a refreshed, more youthful periorbital appearance with effects lasting 10-15 years before additional correction may be needed. Visual field improvement following upper blepharoplasty in patients with severe dermatochalasis obstructing the superior visual field is documented by formal visual field testing and is functionally significant.

DCR for nasolacrimal duct obstruction achieves symptomatic relief (cessation of chronic watering and discharge) in 90-95% of patients with endonasal or external approaches. Orbital decompression for thyroid eye disease reduces proptosis by an average of 3-5 mm per decompressed wall, protecting the cornea, improving cosmesis, and critically, preventing or reversing compressive optic neuropathy (which can cause permanent vision loss if untreated). Reconstruction of eyelid defects following tumour excision achieves complete oncological clearance and satisfactory functional and cosmetic eyelid restoration in the majority of cases.

The most serious risk in oculoplastic surgery is orbital haematoma — rapid-onset post-operative haemorrhage within the confined orbital space that can compress the optic nerve and cause permanent vision loss within hours if not emergently decompressed. This rare but catastrophic complication (occurring in <0.05% of cases) mandates that patients be seen immediately if they develop sudden severe pain, proptosis, or visual loss in the hours following orbital or eyelid surgery. Post-operative ptosis (lagophthalmos — incomplete eye closure) can cause corneal exposure, keratitis, and corneal ulceration in the short term after upper blepharoplasty if too much skin is removed.

Ptosis repair carries a 10-15% risk of under- or overcorrection requiring further adjustment. Dry eye syndrome can be precipitated or worsened by blepharoplasty due to alteration of the eyelid position and blinking mechanics. Chemosis (conjunctival swelling), asymmetry, and visible scarring are additional cosmetic concerns. DCR failure rates of 5-10% may require repeat procedure. Botulinum toxin injection in the periorbital region carries risks of transient eyelid ptosis (3-5% incidence) and rarely diplopia from diffusion into extraocular muscles — both typically resolve within 4-6 weeks as the toxin effect wanes.

Most eyelid procedures are performed as day cases under local anaesthesia with sedation. After upper or lower blepharoplasty, patients apply cold compresses for 48 hours to minimise bruising and swelling, use antibiotic eye drops or ointment for 5-7 days, and sleep with their head elevated. Sutures are removed at 5-7 days. Most bruising resolves in 2-3 weeks, and patients may return to desk work within 7-10 days with cosmetic camouflage. Contact lens wearers should wait 2-3 weeks before resumption. Blurred vision due to lubricating ointment is expected and temporary.

For orbital surgery, hospitalisation of 1-3 days is typically required, with more prolonged follow-up at 2 weeks, 6 weeks, and 3 months. After DCR, regular nasal endoscopic follow-up checks for ostium patency are performed at 1, 3, and 6 months. Oculoplastic surgeons coordinate closely with medical ophthalmologists for patients with thyroid eye disease, ensuring orbital decompression and any subsequent squint or eyelid surgery is sequenced appropriately as the disease evolves.

Oculoplastic procedure costs vary widely by type and setting. Functional procedures (ptosis repair, DCR for symptomatic obstruction, orbital decompression for vision-threatening thyroid eye disease) may be covered by insurance in many countries. Cosmetic blepharoplasty in the UK costs GBP 2,000-5,000, in the USA USD 4,000-8,000, and in Australia AUD 5,000-8,000. Botulinum toxin periorbital injections cost USD 300-600 per session in Western clinics.

India, Thailand, and Turkey offer oculoplastic services at internationally competitive prices. Cosmetic upper and lower blepharoplasty in India at an accredited hospital costs USD 800-2,000 — a 60-75% saving versus USA prices. Thailand's internationally renowned medical tourism infrastructure (Bangkok Bumrungrad, Samitivej hospitals) offers blepharoplasty packages at USD 2,000-4,000 including accommodation. Medical travel for oculoplastic procedures is particularly appealing to Asian international patients given the high density of experienced oculoplastic surgeons in Southeast Asian centres accustomed to managing diverse periorbital anatomies.

For cosmetic periorbital concerns, non-surgical alternatives to blepharoplasty include botulinum toxin for dynamic periorbital wrinkles (crow's feet, forehead lines), hyaluronic acid filler for tear trough hollowing, and skin resurfacing (laser, chemical peel, radiofrequency) for superficial eyelid skin texture and fine lines. These are appropriate for early periorbital ageing but cannot address significant dermatochalasis, orbital fat herniation, or true ptosis.

For functional conditions, ptosis may initially be managed conservatively with protective eyedrops for corneal desiccation, or with ptosis crutches (spectacle-mounted props) for patients unfit for surgery. Thyroid eye disease is first managed medically (selenium supplementation, intravenous methylprednisolone, or rituximab for active inflammatory phase) before surgical decompression is considered. Nasolacrimal duct obstruction from inflammation or infection may transiently respond to antibiotics and topical treatments, but definitive treatment requires DCR surgery. Botulinum toxin is the first-line treatment for blepharospasm before surgical myectomy is considered.